Reported 2 days ago
Alvotech (NASDAQ:ALVO) has formed a commercialization agreement with Advanz Pharma to distribute AVT10, a biosimilar to Cimzia, in Europe. This deal is expected to strengthen Alvotech's position in the biosimilar market and could impact the market share of current treatments for chronic rheumatic diseases.
Source: YAHOO